126 related articles for article (PubMed ID: 31689915)
41. DOT1L promotes expression of CD44 through the Wnt/β-catenin signaling pathway in early gastric carcinoma.
Li P; Zhang Z; Sun P
J Cancer; 2024; 15(8):2276-2291. PubMed ID: 38495505
[TBL] [Abstract][Full Text] [Related]
42. Genome-wide DNA methylation changes upon DOT1L inhibition in hormone-responsive breast cancer cells.
Giurato G; Terenzi I; Chiuso F; Salvati A; Rizzo F; Tarallo R; Weisz A; Nassa G
Front Cell Dev Biol; 2023; 11():1308025. PubMed ID: 38099289
[No Abstract] [Full Text] [Related]
43. RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer.
Di Donato M; Di Zazzo E; Salvati A; Sorrentino C; Giurato G; Fiore D; Proto MC; Rienzo M; Casamassimi A; Gazzerro P; Bifulco M; Castoria G; Weisz A; Nassa G; Abbondanza C
J Transl Med; 2023 Oct; 21(1):736. PubMed ID: 37853459
[TBL] [Abstract][Full Text] [Related]
44. The emerging role of DOT1L in cell proliferation and differentiation: Friend or foe.
Wu D; Zhang J; Jun Y; Liu L; Huang C; Wang W; Yang C; Xiang Z; Wu J; Huang Y; Meng D; Yang Z; Zhou X; Cheng C; Yang J
Histol Histopathol; 2024 Apr; 39(4):425-435. PubMed ID: 37706592
[TBL] [Abstract][Full Text] [Related]
45. Host nasopharyngeal transcriptome dataset of a SARS-CoV-2 positive Italian cohort.
Salvati A; Ferravante C; Lamberti J; Rocco T; Alexandrova E; D'Agostino Y; Sorokin M; Efimov V; Buzdin A; Strianese O; Nassa G; Tarallo R; Weisz A; Rizzo F; Giurato G
Sci Data; 2023 Jun; 10(1):379. PubMed ID: 37316506
[TBL] [Abstract][Full Text] [Related]
46. Gain-of-function mutations in the catalytic domain of
Zhang J; Yang T; Han M; Wang X; Yang W; Guo N; Ren Y; Cui W; Li S; Zhao Y; Zhai X; Jia L; Yang J; Wu C; Wang L
Sci Adv; 2023 Jun; 9(22):eadc9273. PubMed ID: 37256945
[TBL] [Abstract][Full Text] [Related]
47. Streptozotocin-Induced Type 1 and 2 Diabetes Mellitus Mouse Models Show Different Functional, Cellular and Molecular Patterns of Diabetic Cardiomyopathy.
Marino F; Salerno N; Scalise M; Salerno L; Torella A; Molinaro C; Chiefalo A; Filardo A; Siracusa C; Panuccio G; Ferravante C; Giurato G; Rizzo F; Torella M; Donniacuo M; De Angelis A; Viglietto G; Urbanek K; Weisz A; Torella D; Cianflone E
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674648
[TBL] [Abstract][Full Text] [Related]
48. Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancer.
Alexandrova E; Lamberti J; Memoli D; Quercia C; Melone V; Rizzo F; Tarallo R; Giurato G; Nassa G; Weisz A
Cancer Cell Int; 2022 Nov; 22(1):336. PubMed ID: 36333801
[TBL] [Abstract][Full Text] [Related]
49. Insights Into the Role of Epigenetic Factors Determining the Estrogen Response in Estrogen-Positive Ovarian Cancer and Prospects of Combining Epi-Drugs With Endocrine Therapy.
Sarwar S; Alamro A; Huq F; Alghamdi A
Front Genet; 2022; 13():812077. PubMed ID: 35873467
[TBL] [Abstract][Full Text] [Related]
50. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
51. Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.
Alexandrova E; Salvati A; Pecoraro G; Lamberti J; Melone V; Sellitto A; Rizzo F; Giurato G; Tarallo R; Nassa G; Weisz A
Front Genet; 2022; 13():864612. PubMed ID: 35495127
[TBL] [Abstract][Full Text] [Related]
52. The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma.
Ming R; Wang E; Wei J; Shen J; Zong S; Xiao H
Front Oncol; 2021; 11():710694. PubMed ID: 34395285
[TBL] [Abstract][Full Text] [Related]
53. Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis.
Shen YT; Huang X; Zhang G; Jiang B; Li CJ; Wu ZS
Front Oncol; 2021; 11():636365. PubMed ID: 34322374
[TBL] [Abstract][Full Text] [Related]
54. Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Chava S; Bugide S; Edwards YJK; Gupta R
Oncogenesis; 2021 Jul; 10(7):48. PubMed ID: 34253709
[TBL] [Abstract][Full Text] [Related]
55. Higher Integrin Alpha 3 Beta1 Expression in Papillary Thyroid Cancer Is Associated with Worst Outcome.
Mautone L; Ferravante C; Tortora A; Tarallo R; Giurato G; Weisz A; Vitale M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208249
[TBL] [Abstract][Full Text] [Related]
56. Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.
Tan J; Song C; Wang D; Hu Y; Liu D; Ma D; Gao Q
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33891016
[TBL] [Abstract][Full Text] [Related]
57. Histone Modifying Enzymes in Gynaecological Cancers.
Ramarao-Milne P; Kondrashova O; Barry S; Hooper JD; Lee JS; Waddell N
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669182
[TBL] [Abstract][Full Text] [Related]
58. Estrogen Receptor Signaling in Cancer.
Langdon SP
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987743
[TBL] [Abstract][Full Text] [Related]
59. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
[TBL] [Abstract][Full Text] [Related]
60. An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer.
Alexandrova E; Pecoraro G; Sellitto A; Melone V; Ferravante C; Rocco T; Guacci A; Giurato G; Nassa G; Rizzo F; Weisz A; Tarallo R
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32512900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
